Hematology / Oncology CE Activities

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.

Hematology / Oncology
Blog

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).

Hematology / Oncology
Blog

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

Hematology / Oncology
Blog

RMEI Presentations

Answering the Call to Action: How Nurses Have Become Progressively More Involved in Immunotherapy IME (2018 to Present)

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.

Hematology / Oncology
Decision Support Aid

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.

Hematology / Oncology
Decision Support Aid

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

Latest Hematology / Oncology Articles

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma July 2, 2026
In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but an increased risk of grade 3 or higher adverse events.
Toni K. Choueiri, Robert J. Motzer, Jose A. Karam, Wesley Yip, Cristina Suárez, Dingwei Ye, Zhisong He, Christian Caglevic, Tom Ferguson, Yen-Hwa Chang, Carlos Rojas, Roberto Iacovelli, Yüksel Ürün, Elena Verzoni, Juan Carlos Vázquez Limón, Camillo Porta, Robert G. Uzzo, Jae Lyun Lee, Balaji Venugopal, Rana R. McKay, Hans Hammers, Hideaki Miyake, Jad Chahoud, Hong Liu, Joseph E. Burgents, Manish Sharma, Thomas B. Powles, the LITESPARK-022 Investigators*
The Invisible Load of Cognitive Symptoms July 2, 2026
Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them?
Jan Stubberud
Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion June 25, 2026
A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing.
Shampavi Sri Haran, Lucy Cain, Artur Darmanian, Michael Krivanek, Dale Wright, Wayne Nicholls, Martin Lowe, Luciano Dalla-Pozza, Bruce Goodwin, Jane McEniery, Kevin Hardin, Ashleigh Sullivan, Natacha Omer

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.